Zymeworks Added to Nasdaq Biotechnology Index
VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology. The NBI is currently comprised of approximately 250 companies. For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated inclusion in the Nasdaq Biotechnology Index following the annual reconstitution, risks and uncertainties relating to the anticipated trading of Zymeworks securities, and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks relating to becoming included and remaining included in the Nasdaq Biotechnology Index; risks and uncertainties relating to the trading of our securities as it relates to the Nasdaq Biotechnology Index annual reconstitution and the inclusion of Zymeworks on the Nasdaq Biotechnology Index following such reconstitution; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; inability to maintain or enter into new partnerships or strategic collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the other risks described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

TIN LIÊN QUAN
BBS-Bioactive Bone Substitutes: Approved delisting
BBS-Bioactive Bone Substitutes Oyj, Company release, 16 February 2023 at 7.45 pm EET BBS-Bioactive Bone Substitutes: Approved delisting application...
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
THỦ THUẬT HAY
Cách chuyển ảnh thành văn bản trên điện thoại Android
Smartphone hiện nay ngày càng trở nên thông minh, việc chuyển ảnh thành văn bản trực tiếp trên điện thoại không còn là trở ngại và cũng đang là nhu cầu cần thiết của rất nhiều người dùng. Cùng theo dõi bài viết dưới
[Bật mí] Hướng dẫn nạp Tiktok giá rẻ không phải ai cũng biết
Để nâng cao trải nghiệm người dùng, TikTok đã liên tục cập nhật các tính năng mới, trong đó có xu TikTok (hay còn gọi là TikTok Coin). Tuy nhiên, nhiều người dùng vẫn chưa biết cách sử dụng xu TikTok và cách nạp nó như
Thủ thuật macOS: Cách hiển thị dung lượng thư mục
Mặc định Finder trong macOS không hiện dung lượng của folder, chỉ hiện cho file mà thôi. Điều này gây khó khăn cho chúng ta khi cần giám sát folder nào đó hoặc khi cần copy, paste.
3 cách tìm tin nhắn ẩn trên Zalo khi quên tên cực hay mà bạn nên biết
Tin nhắn ẩn trên Zalo giúp ẩn trò chuyện không muốn cho người khác biết. Nhưng lỡ quên tên thì tìm lại như thế nào? Đây là cách tìm tin nhắn ẩn trên Zalo khi quên tên...
Cách tra cứu chứng nhận tiêm vaccine mũi 2 trên thẻ Căn cước công dân
Bạn có thể tra cứu chứng nhận tiêm vaccine mũi 2 trên thẻ CCCD của mình qua ứng dụng VNEID để khai báo khi qua trạm kiểm dịch. Sau đây là cách tra cứu chứng nhận tiêm vaccine mũi 2 trên thẻ Căn cước công dân...
ĐÁNH GIÁ NHANH
realme ra mắt sản phẩm mới kế nhiệm dòng C-series giúp bạn tự tin bước vào giai đoạn “bình thường mới”
Sau hơn 4 tháng giãn cách xã hội, cuộc sống tại nhiều tỉnh thành trên cả nước đã dần trở về trạng thái “bình thường mới”, buộc mọi người phải thích nghi với những thói quen chưa từng có như thường xuyên mở điện thoại
Trên tay Samsung Galaxy F41: Cụm 3 camera sau, chip Exynos 9611, pin 6.000 mAh, giá cả hợp lý
Mới đây, Samsung đã chính thức ra mắt phiên bản đầu tiên thuộc dòng Galaxy F với viên pin siêu khủng và mức giá hợp lý. Galaxy F41 dự kiến sẽ “đối đầu” với rất nhiều sản phẩm cùng cấp thuộc dòng OPPO, Realme, Redmi và
So sánh cấu hình, hiệu năng Snapdragon 625 và Exynos 7872: Lựa chọn nào tốt hơn?
Mới đây, Samsung vừa chính thức ra mắt bộ vi xử lý mới thuộc phân khúc tầm trung của hãng là Exynos 7872 và nó đã được trang bị trên chiếc smartphone vừa mới ra mắt của Meizu là M6s.